Fate Therapeutics (FATE) Long-Term Debt Repayments (2013 - 2019)
Fate Therapeutics' (FATE) quarterly Long-Term Debt Repayments came in at $14.0 million in Q4 2019, up 108.67% on a QoQ basis from $6.7 million in Q3 2017.
Fate Therapeutics (FATE) Long-Term Debt Repayments (2013 - 2019) Analysis & Trends
Fate Therapeutics (FATE) has 6 years of Long-Term Debt Repayments data on file, last reported at $14.0 million in Q4 2019.
- Quarterly Long-Term Debt Repayments changed N/A year-over-year to $14.0 million in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $22.7 million (changed N/A YoY) and the FY2019 annual result came in at $15.0 million, changed N/A from the prior year.
- Long-Term Debt Repayments improved to $14.0 million in Q4 2019, from $6.7 million in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $14.0 million in Q4 2019 to a low of $600000.0 in Q3 2015.
- A 4-year average of $3.4 million and a median of $1.9 million in 2016 frame the typical range for Long-Term Debt Repayments.
- Annual changes were most pronounced in 2015 — Long-Term Debt Repayments declined 20.0% — and 2017, when it jumped 253.11%.
- Tracing FATE's Long-Term Debt Repayments over 4 years: stood at $935000.0 in 2015, then surged by 111.23% to $2.0 million in 2016, then jumped by 239.7% to $6.7 million in 2017, then surged by 108.67% to $14.0 million in 2019.
- The last three Long-Term Debt Repayments figures came in at $14.0 million (Q4 2019), $6.7 million (Q3 2017), and $2.0 million (Q2 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 17.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 14.00 Mn |
| Dec 31, 2019 | 14.00 Mn |
| Sep 30, 2017 | 6.71 Mn |
| Sep 30, 2017 | 6.71 Mn |
| Jun 30, 2017 | 2.00 Mn |
| Jun 30, 2017 | 2.00 Mn |
| Mar 31, 2017 | 2.01 Mn |
| Mar 31, 2017 | 2.01 Mn |
| Dec 31, 2016 | 1.98 Mn |
| Dec 31, 2016 | 1.98 Mn |
| Sep 30, 2016 | 1.90 Mn |
| Sep 30, 2016 | 1.90 Mn |
| Jun 30, 2016 | 1.90 Mn |
| Jun 30, 2016 | 1.90 Mn |
| Mar 31, 2016 | 1.87 Mn |
| Mar 31, 2016 | 1.87 Mn |
| Dec 31, 2015 | 935,000.00 |
| Dec 31, 2015 | 935,000.00 |
| Sep 30, 2015 | 600,000.00 |
| Sep 30, 2015 | 600,000.00 |